OrbiMed, a US-based life sciences investment firm, has announced raising more than $4.3 billion in commitments for its latest private investment funds, which include its fifth Asia-focused healthcare vehicle OrbiMed Asia Partners V.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
